We are focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings
Year founded1997
Served areaEurope
HeadquartersWeinbergweg 22, 06120 Halle (Germany) – Netherlands
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
01.04.22 | E. Platzer | Executive member | Buy | EUR 1,299,994.50 |
01.04.22 | U. Dauer | Executive member | Buy | EUR 49,990.50 |
02.12.20 | D.J. von der Osten | Executive member | Buy | EUR 112,400.00 |
30.11.20 | M. Schaeffer | Executive member | Other | EUR 0.00 |
Position Holder | Short Interest in Percent | Date |
---|---|---|
Janus Henderson Investors UK Limited | 0.59% | 22.06.23 |
Total | 0.59% |
NL00150002Q7
LEI3912004AMB0KGZXZYJ15
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.